Mission Therapeutics Invited to Present at UBS Innovation Series: The Next Wave in Neurodegeneration

CAMBRIDGE, UK – 2 June 2021Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced today that Paul Thompson, Chief Scientific Officer (CSO), will present at the upcoming Next Wave in Neurodegeneration Investor event (3 June), as part of the UBS Innovation Series.

Paul will present on Mission’s world-leading DUB platform and pipeline, including the potential of the Company’s lead in-house target, USP30, in treating neurodegenerative diseases, and will provide Mission’s perspective on the current research and development (R&D) landscape in this field. Paul’s 30 minute presentation will be followed by a Q&A session.

The Next Wave in Neurodegeneration Investor event brings together investors and innovative private companies engaged in R&D with a focus on neurodegenerative diseases. Executives will share an overview of the next-generation approaches companies are adopting to treat diseases such as Amyotrophic Lateral Sclerosis (ALS), Huntington’s, and Parkinson’s, and will discuss any successes and failures in their effort to achieve neurodegenerative modification.

– ENDS –


Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0)1223 607 340

Instinctif Partners
Melanie Toyne-Sewell / Katie Duffell
Tel: +44 (0) 20 7457 2013


About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Prof. Steve Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company also has secured major industry partnerships, including its collaboration with AbbVie in November 2018, for the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease. The Company is managed by a team with broad international, commercial and clinical-science experience.

To date the Company has received £73 million /$101 million in funding and its investors comprise blue chip institutional and corporate investors including: Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group and Rosetta Capital. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

For more information, please visit our website, www.missiontherapeutics.com, or follow us on Twitter or LinkedIn.